Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you remember the presentation the CEO said they had a couple of parties interested in the RX-3117 compound. My guess is that a partnership is nearing close for Rexahn. Tomorrow is gonna be a great day!
Looking good for today we seemed to consolidate a bit here by $6 hopefully more volume can send us higher tomorrow! Anyways Next Monday March 3 we should see news before the Wall Street Analyst Forum presentation. Good luck to all here in RXII!
"RXi Pharmaceuticals to Present at the 24th Annual Wall Street Analyst Forum"
http://finance.yahoo.com/news/rxi-pharmaceuticals-present-24th-annual-120200868.html
Seems good to go and present at a lot of big investors at Wall Street. Hopefully we will have phase 2a hypertrophic results by then!
I wrote my new article for Arrowhead Research Corp for Seeking Alpha. It can be viewed here. Enjoy: http://seekingalpha.com/article/2030641-arrowhead-a-functional-cure-for-the-hepatitis-b-virus
Nice price target. Although if phase 2a results on hypertrophic scars come out real good I'm expecting $20 per share or more easily.
Found a good article from a Blog website! Pretty good read on Rxi Pharmaceuticals (RXII) http://www.biotechpicklist.com/rxi-pharmaceuticals-an-rnai-biotech-to-invest-in-before-the-big-jump/
Stop? hehe check out ACTC it has like 6 billion outstanding shares and still climbing. Koos will continue to dilute this to earn a paycheck that's the bottom line for BMSN.
News out this Morning RXII uplisted to NASDAQ capital Market! Enjoy everyone and good luck to all of us long term holders! http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-listing-nasdaq-120200192.html
Wow nice find you beat me to it. I Just caught it now we gonna get big institutional investors, and analyst coverage. Plus maybe higher volume. Grats to all of us longs!
RXI-109
1. Started a phase 2a trial for hypertrophic scars November 15th 2013, and it is expected to last at least 1 year.
2. RXI-109 for Keloid removal is set to start Q1 2014 so at least before March 2014.
3. RXI-109 for breast surgery scars is set to start late Q2/ early Q3 2014 phase 2a.
All trials are expected to release initial scar reduction results 3 months after trial starts. So it is possible by late feb/early march we will see some initial data for the phase 2a hypertrophic scar study.
Yep got very excited with that news. With that filing common shares are being converted from OtC to NASDAQ common shares. I think the uplisting will be a huge next step going forward for Rxi pharmaceuticals. It will only get better from here!
A response to the latest SA article published for GAlena Biopharma! http://www.biotechpicklist.com/galena-biopharma-bucking-the-trend-against-short-sellers/
I hope you guys like the SA article I wrote on IDRA http://seekingalpha.com/article/1979931-idera-pharmaceuticals-set-to-ride-a-200-percent-gain-in-2014
that's means we should see uplist soon then!
very good article on Seeking Alpha About Novavax (NVAX) http://seekingalpha.com/article/1940561-novavax-a-biotech-story-set-to-double-in-2014?source=yahoo
Supinoxin phase 1 results are expected Q1 2014 to show anti-tumor activity. Positive results on that compound and RNN goes higher. Also the offering closed today, so tomorrow I expect new investors and a bounce coming tomorrow.
New Seeking Alpha Article for GALE that mentions a little about RXII
http://seekingalpha.com/article/1955041-emerging-biotech-takes-aim-at-preventing-recurrent-breast-cancer?source=yahoo
Should be a good day today, patent news out. RXII received patent for self delivering sd-rxRNA platform for CTGF in RXI-109 (anti scarring) and other fibrotic disorders (liver disease/liver fibrosis)http://finance.yahoo.com/news/rxi-pharmaceuticals-receives-us-notice-120200320.html
I agree should be a good day today, hopefully uplistng to NASDAQ news
Wrote an article for NVAX on Seeking Alpha hope you guys like it! http://seekingalpha.com/article/1940561-novavax-a-biotech-story-set-to-double-in-2014
RXI-109 is worth $5 billion market value alone, RXI-209 liver disease/liver fibrosis another $5 billion dollar market, and ophthalmology pipeline another $5 billion dollar market. Now you can see why Dr. Frost is in this he sess $$$$$$$$$$$$$$$$
I was lonely on this board for the longest time..........:( good to see others on here we should move up greatly once we uplist to the NASDAQ!!
Hope you all read my article and got in early for a big run. http://seekingalpha.com/article/1911591-rexahn-a-turn-around-story-for-2014 but you gotta read it soon cause Jan 22 it is heading to SA PRO because it got small cap insight.
No worries now we can uplist to the NASDAQ, then the real boom upwards will begin.
Rexahn will present at the 2014 Biotech Showcase on Jan 14th 2013 at 9:30 a.m PST http://finance.yahoo.com/news/rexahn-pharmaceuticals-present-biotech-showcase-130000359.html
Yes I'm still holding shares of RXII it is still way undervalued for the potential. As for ONCS I have a good amount of shares like INO! All will be good long term plays!
Wrote an Article for Seeking Alpha apparently it didn't add sufficient ideas than previous articles so it got denied. I think it should have been approved, but whatever I'm posting it here for you guys to read. I just posted it on my SA instablog instead! http://seekingalpha.com/instablog/1058124-long-term-bio/2518561-oncosec-medical-the-game-changer-in-the-biotech-industry
I hope you enjoy my article, it took awhile to write it. Next one will be on ONCS!
Yes I wrote it took about one whole week to write it. I also got small cap insight on it! Hope you enjoyed it!
Hope you guys like my SA article I made. I got small cap Insight on it! Enjoy! http://seekingalpha.com/article/1900321-cellceutix-an-undiscovered-company-set-to-rise-in-2014
Wait a second here? More trials? Why wasn't this trial and the other safety trials done before the IND to the FDA? It's like this company went backwards. IND first then trials lol how silly. Trials first for toxicity and safety then file IND what a bunch of noobs they are.
Interesting if you check out RXII quote on OTCQX it seems to have the prices greyed out and closed. I wonder if it had to do with the bots manipulating the price.
Found out from IR NITE and CANT are both robots. If you look on level 2 on OTCQX you can see bids and ask by the same company at the same time with 100 share lots. Now if you know any investors who dabbles with 100 shares : selling and buying 100 shares at the same time please do let me know!
Their not buying because they see the electronic trading machines bring the share price down everyday. With 4 to 5 pieces of good news we should have been way higher by now. But have been stopped by this manipulation. My advice though is if you believe in RXII then stay long, I know I am.
Awesome new Seeking Alpha Article talking about potential for MM- 398 http://seekingalpha.com/article/1886611-merrimack-opportunity-to-increase-share-price-by-100-in-2014
Yes wild, the manipulation on the OTC market by NITE and CANT aside, Rxi's sd-rxRNA technology is amazing as a "self delivering" RNAi. I mean I don't understand why people are not impressed, you have the only company in the world to produce RNAi oligonucleotides with no delivery vehicle required.
Alnylam, Tekmira, Arrowhead, silence etc. all require a delivery method which takes away from the efficacy. This is because all those companies have to encapsulate the RNAi oligonucleotide into a lipid/nanoparticle to deliver it into cells. Rxi requires nothing but the RNAi strand itself.
Look at what Rxi is targeting after RXI-109 for scarring. They are going after Regeneron's market with macular degeneration, diabetic eye disease, PVR, Retinoblastoma. This company is a long term keeper!
Well you can Thank NITE and CANT for that!
New results out. Very good by adding a 4th cohort in dosing 10mg mRNA gene knockdown is increased from 43% up to 50%! Very good results, shows the drug to work in a dose dependent manner. http://ih.advfn.com/p.php?pid=nmona&article=60262311
Yes RXII has the potential to do well. It is currently being controlled though right now by NITE and CANT unfortunately. Tomorrow though is Piper Jaffray Healthcare conference, so we might get some trial news on the extended multi dose cohort results.
This company should change it's name to Dilution Machine ticker symbol (DLMN) lol. Glad I don't own this stock!